<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01618019</url>
  </required_header>
  <id_info>
    <org_study_id>HYUH-C55</org_study_id>
    <secondary_id>KRF-2010-000-8656</secondary_id>
    <nct_id>NCT01618019</nct_id>
  </id_info>
  <brief_title>N-3 PUFA and Rheumatoid Arthritis in Korea</brief_title>
  <official_title>Effect of n-3 Polyunsaturated Fatty Acid Supplementation on Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanyang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanyang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if supplementation of n-3 polyunsaturated fatty acid
      (PUFA) can be beneficial for the patients with rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose of NSAID</measure>
    <time_frame>16 week</time_frame>
    <description>Daily non-steroidal anti-inflammatory drug (NSAID) requirements as mg/day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Morning Stiffness</measure>
    <time_frame>16 week</time_frame>
    <description>Duration of morning stiffness means that patients with rheumatoid arthritis feel those joints stiff when they wake up in the morning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Assessment</measure>
    <time_frame>16 week</time_frame>
    <description>Physician's global assessment is ranged from 0 to 10 by the assessing physician.
(0= no pain; 10= very severe pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Assessment</measure>
    <time_frame>16 week</time_frame>
    <description>Patient's global assessment is patient self-assessed disability. (0= better condition; 10= very worse condition)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scale</measure>
    <time_frame>16 week</time_frame>
    <description>Pain scale is ranged from 0 to 100. (0= no pain; 100= severe pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteocalcin Concentration</measure>
    <time_frame>16 week</time_frame>
    <description>serum Osteocalcin concentration as nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BSAP Concentration</measure>
    <time_frame>16 week</time_frame>
    <description>serum bone specific alkaline phosphatase concentration as U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTX Concentration</measure>
    <time_frame>16 week</time_frame>
    <description>serum C-terminal telopeptide of type 1 collagen concentration as nmol/L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>N-3 PUFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 capsules/day of n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3 fatty acid</intervention_name>
    <description>5 capsules/day of either n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid</description>
    <arm_group_label>N-3 PUFA</arm_group_label>
    <other_name>Ropufa 75 n-3, DSM Nutritional products, Switzerland</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with rheumatoid arthritis diagnosed based on American College of Rheumatology
             guideline and receiving NSAID, glucocorticoids, or DMARD were eligible if the dosage
             had been stable for at least 3 months prior to entering the study.

        Exclusion Criteria:

          -  Patients were excluded if they were pregnant, lactating, under the age of 18 or over
             age 80, taking supplements containing n-3 PUFA, white blood cell (WBC) ≤ 3.5 × 109/L,
             hemoglobin (Hb) ≤ 8.5 g/dL, platelet ≤ 100 × 109/L, creatinine ≥ 2.0 mg/dL, and
             aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 2.5 times upper
             limit of normal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongsoon Park, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanyang University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hanyang university hospital</name>
      <address>
        <city>Seoul</city>
        <zip>133-792</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2012</study_first_submitted>
  <study_first_submitted_qc>June 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2012</study_first_posted>
  <results_first_submitted>June 17, 2012</results_first_submitted>
  <results_first_submitted_qc>August 30, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 2, 2012</results_first_posted>
  <last_update_submitted>August 30, 2012</last_update_submitted>
  <last_update_submitted_qc>August 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hanyang University</investigator_affiliation>
    <investigator_full_name>Yongsoon Park</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>n-3 PUFA</keyword>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>inflammation</keyword>
  <keyword>eicosanoids</keyword>
  <keyword>bone turnover markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with rheumatoid arthritis diagnosed based on American College of Rheumatology guideline were recruited from Hanyang university hospital in Seoul, Eulji university hospital in Daejun, Catholic university hospital in Daegu, and Maryknoll medical center in Busan between Dec 2010 and Dec 2011.</recruitment_details>
      <pre_assignment_details>Patients receiving NSAID, glucocorticoids, or DMARD were eligible if the dosage had been stable for at least 3 months prior to entering the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>N-3 PUFA</title>
          <description>5 capsules/day of n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>N-3 PUFA</title>
          <description>5 capsules/day of n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="109"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.51" spread="10.71"/>
                    <measurement group_id="B2" value="48.67" spread="8.91"/>
                    <measurement group_id="B3" value="49.09" spread="9.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dose of NSAID</title>
        <description>Daily non-steroidal anti-inflammatory drug (NSAID) requirements as mg/day</description>
        <time_frame>16 week</time_frame>
        <population>Per-protocol analysis (except for drop out patients) Measurement of NSAID requirements at 16 weeks, except for 10 in N-3 PUFA and 6 in placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>N-3 PUFA</title>
            <description>5 capsules/day of n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)</description>
          </group>
        </group_list>
        <measure>
          <title>Dose of NSAID</title>
          <description>Daily non-steroidal anti-inflammatory drug (NSAID) requirements as mg/day</description>
          <population>Per-protocol analysis (except for drop out patients) Measurement of NSAID requirements at 16 weeks, except for 10 in N-3 PUFA and 6 in placebo.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="319.72" spread="407.10"/>
                    <measurement group_id="O2" value="301.58" spread="337.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Morning Stiffness</title>
        <description>Duration of morning stiffness means that patients with rheumatoid arthritis feel those joints stiff when they wake up in the morning.</description>
        <time_frame>16 week</time_frame>
        <population>Per-protocol analysis (except for drop out patients) Measurement of Morning stiffness assessment at 16 weeks, except for 16 in N-3 PUFA and 16 in placebo</population>
        <group_list>
          <group group_id="O1">
            <title>N-3 PUFA</title>
            <description>5 capsules/day of n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Morning Stiffness</title>
          <description>Duration of morning stiffness means that patients with rheumatoid arthritis feel those joints stiff when they wake up in the morning.</description>
          <population>Per-protocol analysis (except for drop out patients) Measurement of Morning stiffness assessment at 16 weeks, except for 16 in N-3 PUFA and 16 in placebo</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.10" spread="79.28"/>
                    <measurement group_id="O2" value="17.55" spread="29.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician’s Global Assessment</title>
        <description>Physician’s global assessment is ranged from 0 to 10 by the assessing physician.
(0= no pain; 10= very severe pain)</description>
        <time_frame>16 week</time_frame>
        <population>Per-protocol analysis (except for drop out patients) Measurement of Physician’s global assessment at 16 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>N-3 PUFA</title>
            <description>5 capsules/day of n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)</description>
          </group>
        </group_list>
        <measure>
          <title>Physician’s Global Assessment</title>
          <description>Physician’s global assessment is ranged from 0 to 10 by the assessing physician.
(0= no pain; 10= very severe pain)</description>
          <population>Per-protocol analysis (except for drop out patients) Measurement of Physician’s global assessment at 16 weeks.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="1.83"/>
                    <measurement group_id="O2" value="1.60" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient’s Global Assessment</title>
        <description>Patient’s global assessment is patient self-assessed disability. (0= better condition; 10= very worse condition)</description>
        <time_frame>16 week</time_frame>
        <population>Per-protocol analysis (except for drop out patients) Measurement of Patient’s global assessment at 16 week.</population>
        <group_list>
          <group group_id="O1">
            <title>N-3 PUFA</title>
            <description>5 capsules/day of n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)</description>
          </group>
        </group_list>
        <measure>
          <title>Patient’s Global Assessment</title>
          <description>Patient’s global assessment is patient self-assessed disability. (0= better condition; 10= very worse condition)</description>
          <population>Per-protocol analysis (except for drop out patients) Measurement of Patient’s global assessment at 16 week.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="2.57"/>
                    <measurement group_id="O2" value="4.01" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scale</title>
        <description>Pain scale is ranged from 0 to 100. (0= no pain; 100= severe pain)</description>
        <time_frame>16 week</time_frame>
        <population>Per-protocol analysis (except for drop out patients) Measurement of Pain scale at 16 week.</population>
        <group_list>
          <group group_id="O1">
            <title>N-3 PUFA</title>
            <description>5 capsules/day of n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scale</title>
          <description>Pain scale is ranged from 0 to 100. (0= no pain; 100= severe pain)</description>
          <population>Per-protocol analysis (except for drop out patients) Measurement of Pain scale at 16 week.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.85" spread="26.41"/>
                    <measurement group_id="O2" value="28.75" spread="20.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Osteocalcin Concentration</title>
        <description>serum Osteocalcin concentration as nmol/L</description>
        <time_frame>16 week</time_frame>
        <population>Per-protocol anlysis (except for drop out patients) serum Osteocalcain concentration at 16 week</population>
        <group_list>
          <group group_id="O1">
            <title>N-3 PUFA</title>
            <description>5 capsules/day of n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)</description>
          </group>
        </group_list>
        <measure>
          <title>Osteocalcin Concentration</title>
          <description>serum Osteocalcin concentration as nmol/L</description>
          <population>Per-protocol anlysis (except for drop out patients) serum Osteocalcain concentration at 16 week</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="0.36"/>
                    <measurement group_id="O2" value="0.87" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BSAP Concentration</title>
        <description>serum bone specific alkaline phosphatase concentration as U/L</description>
        <time_frame>16 week</time_frame>
        <population>Per-protocol analysis (except for drop out patients) serum bone specific alkaline phosphatase concentration at 16 week</population>
        <group_list>
          <group group_id="O1">
            <title>N-3 PUFA</title>
            <description>5 capsules/day of n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)</description>
          </group>
        </group_list>
        <measure>
          <title>BSAP Concentration</title>
          <description>serum bone specific alkaline phosphatase concentration as U/L</description>
          <population>Per-protocol analysis (except for drop out patients) serum bone specific alkaline phosphatase concentration at 16 week</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.31" spread="4.85"/>
                    <measurement group_id="O2" value="12.27" spread="5.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CTX Concentration</title>
        <description>serum C-terminal telopeptide of type 1 collagen concentration as nmol/L</description>
        <time_frame>16 week</time_frame>
        <population>Per-protocol analysis (except for drop out patients) serum C-terminal telopeptide of type 1 collagen concentration at 16 week</population>
        <group_list>
          <group group_id="O1">
            <title>N-3 PUFA</title>
            <description>5 capsules/day of n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)</description>
          </group>
        </group_list>
        <measure>
          <title>CTX Concentration</title>
          <description>serum C-terminal telopeptide of type 1 collagen concentration as nmol/L</description>
          <population>Per-protocol analysis (except for drop out patients) serum C-terminal telopeptide of type 1 collagen concentration at 16 week</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="1.05"/>
                    <measurement group_id="O2" value="1.35" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>N-3 PUFA</title>
          <description>5 capsules/day of n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Yongsoon Park</name_or_title>
      <organization>Hanyang University</organization>
      <phone>82-2-2220-1205</phone>
      <email>yongsoon@hanyang.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

